Healius
Market Cap
AU$1.9b
Last Updated
2020/02/16 10:30 UTC
Data Sources
Company Financials +
Executive Summary
Healius Limited provides various services and facilities to general practitioners, specialists, dentists, IVF specialists, and other healthcare professionals operating in the bulk billing and private billing sector in Australia.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with reasonable growth potential.
Similar Companies
Share Price & News
How has Healius's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HLS has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
1.4%
HLS
0.8%
AU Healthcare
1.4%
AU Market
1 Year Return
3.8%
HLS
26.9%
AU Healthcare
16.1%
AU Market
Return vs Industry: HLS underperformed the Australian Healthcare industry which returned 26.9% over the past year.
Return vs Market: HLS underperformed the Australian Market which returned 16.1% over the past year.
Shareholder returns
| HLS | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.4% | 0.8% | 1.4% |
| 30 Day | 1.4% | 2.3% | 0.5% |
| 90 Day | -3.2% | 6.4% | 4.8% |
| 1 Year | 6.4%3.8% | 30.9%26.9% | 21.2%16.1% |
| 3 Year | 0.6%-10.2% | 25.0%13.6% | 37.0%18.6% |
| 5 Year | -21.1%-34.6% | 34.1%15.0% | 51.7%17.8% |
Price Volatility Vs. Market
How volatile is Healius's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Why You Should Care About Healius Limited’s (ASX:HLS) Low Return On CapitalValuation
Is Healius undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HLS (A$2.98) is trading below our estimate of fair value (A$13.38)
Significantly Below Fair Value: HLS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HLS is poor value based on its PE Ratio (32.4x) compared to the Healthcare industry average (19.4x).
PE vs Market: HLS is poor value based on its PE Ratio (32.4x) compared to the Australian market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: HLS is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (0.9x) compared to the AU Healthcare industry average (1.9x).
Next Steps
Future Growth
How is Healius forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
22.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS's forecast earnings growth (22.3% per year) is above the savings rate (1.1%).
Earnings vs Market: HLS's earnings (22.3% per year) are forecast to grow faster than the Australian market (9.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HLS's revenue (4.5% per year) is forecast to grow faster than the Australian market (4.1% per year).
High Growth Revenue: HLS's revenue (4.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLS's Return on Equity is forecast to be low in 3 years time (5.8%).
Next Steps
Past Performance
How has Healius performed over the past 5 years?
-38.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLS has high quality earnings.
Growing Profit Margin: HLS's current net profit margins (3.1%) are higher than last year (0.2%).
Past Earnings Growth Analysis
Earnings Trend: HLS has become profitable over the past 5 years, growing earnings by -38.1% per year.
Accelerating Growth: HLS's earnings growth over the past year (1263.4%) exceeds its 5-year average (-38.1% per year).
Earnings vs Industry: HLS earnings growth over the past year (1263.4%) exceeded the Healthcare industry 1.8%.
Return on Equity
High ROE: HLS's Return on Equity (2.7%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Healius's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets (A$346.5M) do not cover its short term liabilities (A$391.9M).
Long Term Liabilities: HLS's short term assets (A$346.5M) do not cover its long term liabilities (A$903.5M).
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (39.9%) is considered satisfactory.
Reducing Debt: HLS's debt to equity ratio has reduced from 46.9% to 39.9% over the past 5 years.
Balance Sheet
Inventory Level: HLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: HLS's debt is not covered by short term assets (assets are 0.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HLS is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: HLS is profitable, therefore cash runway is not a concern.
Next Steps
Dividend
What is Healius's current dividend yield, its reliability and sustainability?
2.42%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: HLS's dividend (2.42%) is higher than the bottom 25% of dividend payers in the Australian market (2.29%).
High Dividend: HLS's dividend (2.42%) is low compared to the top 25% of dividend payers in the Australian market (5.5%).
Stability and Growth of Payments
Stable Dividend: HLS's dividend payments have been volatile in the past 10 years.
Growing Dividend: HLS's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (78.2%), HLS's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HLS's dividends in 3 years are forecast to be covered by earnings (54.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.5yrs
Average management tenure
CEO
Malcolm Parmenter (64yo)
2.4yrs
Tenure
AU$1,899,523
Compensation
Dr. Malcolm W. Parmenter, MB, BS, MAICD, has been the Managing Director and Chief Executive Officer at Primary Health Care Limited since September 06, 2017. Dr. Parmenter served as the Chief Executive Offi ...
CEO Compensation Analysis
Compensation vs Market: Malcolm's total compensation ($USD1.28M) is about average for companies of similar size in the Australian market ($USD1.35M).
Compensation vs Earnings: Malcolm's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 2.4yrs | AU$1.90m | 0.014% A$253.5k | |
| Chief Financial Officer | 0.5yrs | AU$710.97k | 0.0080% A$147.9k | |
| Chief Executive of Imaging | 4.3yrs | AU$773.74k | 0.0050% A$92.2k | |
| Group Executive of People & Shared Services | 0.3yrs | no data | no data | |
| Chief Executive of Medical Centre | 0.3yrs | no data | no data | |
| Chief Executive of the Pathology Division | 0.5yrs | no data | no data | |
| CEO of Montserrat Day Hospitals | 0.3yrs | no data | no data | |
| Company Secretary | 5yrs | no data | no data | |
| Additional Company Secretary | 0.5yrs | no data | no data | |
| Group Executive of Corporate Affairs | 4.6yrs | no data | no data |
0.5yrs
Average Tenure
Experienced Management: HLS's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 2.4yrs | AU$1.90m | 0.014% A$253.5k | |
| Non-Executive Director | 7.5yrs | AU$169.48k | 0.0026% A$47.5k | |
| Non-Executive Director | 4.5yrs | AU$170.68k | 0.0089% A$166.1k | |
| Non-Executive Director | 9.3yrs | AU$157.50k | 0.0065% A$121.0k | |
| Chairman | 1.6yrs | AU$292.02k | 0.012% A$229.4k | |
| Independent Non-Executive Director | 1.5yrs | AU$134.22k | 0.0024% A$44.7k |
3.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: HLS's board of directors are considered experienced (3.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.
Top Shareholders
Company Information
Healius Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Healius Limited
- Ticker: HLS
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$1.856b
- Shares outstanding: 622.74m
- Website: https://www.healius.com.au
Number of Employees
Location
- Healius Limited
- 203 Pacific Highway
- Level 6
- St Leonards
- New South Wales
- 2065
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PHCR.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 1998 |
| HLS | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
| PGZ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 1998 |
| HLS | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
Biography
Healius Limited provides various services and facilities to general practitioners, specialists, dentists, IVF specialists, and other healthcare professionals operating in the bulk billing and private billing sector in Australia. It operates through three segments: Pathology, Medical Centres, and Imaging. The company offers diagnostic imaging services, including X-ray, ultrasound, computerized tomography, mammography, magnetic resonance imaging, nuclear medicine, positron emission tomography, and interventional radiology; and private medical laboratory and pathology services. It also operates medical centers that provide a range of specialist services, such as dental, physiotherapy, occupational health, allied health, IVF, eye specialist, skin specialist, skin cancer check, and consultant specialist services, as well as scanning services from standalone imaging sites, hospitals, and medical centers. The company operates 2,318 pathology laboratories and collection centers; 95 medical centers and day hospitals; and 145 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in St Leonards, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 10:30 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.